Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canagliflozin vs Dulaglutide: Dulaglutide has the stronger overall evidence (7 vs 4.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dulaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Canagliflozin and Dulaglutide have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing (e.g. 100–300 mg once daily before the first meal) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (canagliflozin)
Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.
any
Subcutaneous once-weekly pen (Trulicity)
Unknown in humans
Months to years
Weeks to months
Throughout use
Weeks to months
Months to years
Months
Especially during initiation/escalation
Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight (2020) · Animal
NIA Interventions Testing Program: canagliflozin extended lifespan in male mice
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial (empagliflozin, same class)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
The New England journal of medicine (2021) · Rct
EMPEROR-Preserved randomized trial (empagliflozin)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Multicentre, double-blind, placebo-controlled cardiovascular-outcomes RCT: 9,901 patients aged ≥50 with type 2 diabetes, randomized to subcutaneous dulaglutide 1.5 mg/week or placebo at 371 sites in 24 countries
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet Diabetes Endocrinol (2019) · Meta analysis
Meta-analysis of seven GLP-1 receptor agonist cardiovascular-outcomes trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6); 56,004 participants
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Pre-specified exploratory analysis of the REWIND trial (9,901 participants) examining the renal component of the composite microvascular outcome
Dulaglutide has a higher evidence score (7/10 vs 4.5/10) and wins in 2 of 3 categories.
For manage blood sugar, Dulaglutide has a higher relevance score (82 vs 60).
No known interactions between Canagliflozin and Dulaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.